CancerDrs Find care

Stomach Cancer clinical trials in Louisiana

11 actively recruiting stomach cancer trials at 7 sites across Louisiana.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresec…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05677490
Sites in Louisiana:
  • University Medical Center New Orleans — New Orleans, Louisiana
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting NIH

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from wh…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06203600
Sites in Louisiana:
  • Ochsner Hematology Oncology North Shore - Covington (West Region) — Covington, Louisiana
  • Ochsner Medical Center Jefferson — New Orleans, Louisiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+),…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06784752
Sites in Louisiana:
  • LSU Medical Center — New Orleans, Louisiana
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or…

Sponsor: AstraZeneca
NCT ID: NCT05702229
Sites in Louisiana:
  • Research Site — Baton Rouge, Louisiana
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.

Sponsor: Coherus Oncology, Inc.
NCT ID: NCT06657144
Sites in Louisiana:
  • Ochsner Health — New Orleans, Louisiana
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Louisiana:
  • LSU Health Baton Rouge-North Clinic — Baton Rouge, Louisiana
  • Our Lady of the Lake Physician Group — Baton Rouge, Louisiana
  • Our Lady of The Lake — Baton Rouge, Louisiana
  • Louisiana Hematology Oncology Associates LLC — Baton Rouge, Louisiana
  • Louisiana Hematology Oncology Associates — Baton Rouge, Louisiana
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Louisiana:
  • Massive Bio SYNERGY-AI site — New Orleans, Louisiana
View on ClinicalTrials.gov →
Recruiting Industry

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinica…

Sponsor: Guardant Health, Inc.
NCT ID: NCT05059444
Sites in Louisiana:
  • Tulane Cancer Center — New Orleans, Louisiana
  • Christus Highland/ Boniol — Shreveport, Louisiana
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20